secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexaria Bioscience Corp. (LEXX)
CIK:        0001348362
Form:       8-K
Filed at:   2025-06-12T23:59:59+00:00
Accession:  0001640334-25-001030
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 1.0
LLM model:  deepseek-v4-flash:cloud@v2

Lexaria expands GLP-1-H24-4 trial with 5th tirzepatide arm
----------------------------------------------------------

- Added 5th study arm investigating DehydraTECH-tirzepatide capsules in GLP1-H24-4 diabetes trial.
- Existing four arms increased from 20 to 24 subjects; new arm will recruit 24 subjects.
- Change Order with Novotech adds ~AU$1,900,000 to approved budget.
- Human research ethics committee approval for the new arm was granted Feb 24, 2025.
- Study evaluates DehydraTECH delivery of cannabidiol and GLP-1 agonists in pre/Type II diabetes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348362/000164033425001030/0001640334-25-001030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348362/000164033425001030/lxrp_8k.htm
  HTML page:      https://secwatch.observer/filing/0001640334-25-001030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer